Clinical Trial Update: A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib [Phase 1, Phase 2]

View source ↗

Summary

A multi-site Phase I/II trial at MD Anderson Cancer Center is evaluating the combination of venetoclax (BCL-2 inhibitor) and revumenib (menin inhibitor) in acut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Revumenib (revumenib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: RECRUITING